Semaglutide Obesity Trial

Brief description of study

The purpose of this study is to determine if semaglutide may reduce the risk of having cardiovascular events (stroke, heart attack, and other conditions that damage the heart) in patients with overweight or obesity who have prior cardiovascular disease (CVD), a condition involving the narrowing or blocking of blood vessels, which can lead to cardiovascular events such as heart attack or stroke. Semaglutide is a medicine doctors prescribe in some countries (including the United States) to treat Type 2 Diabetes. It is considered an investigational drug in this study for two reasons: 1. The dose of semaglutide being used in the study is higher than the dose currently used in practice to treat Type 2 Diabetes, and 2. Semaglutide is not currently approved by the US Food and Drug Administration (FDA) for weight management and reduction of cardiovascular events in people with overweight or obesity and CVD.

Clinical Study Identifier: s18-00450 Identifier: NCT02906930

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.